YZYBIO-B (02496) announced its mid-term performance, with a net loss of 58.834 million RMB, a 25% narrowing year-on-year.

YZYBIO-B (02496) released its performance for the six months ending June 30, 2025, with a revenue of 37.187 million yuan (RMB, same below); a net loss of 58.834 million yuan, a 25% decrease compared to the same period last year; and a basic loss per share of 0.30 yuan. During the reporting period, the revenue includes license fee income and research and development service income. License fee income mainly comes from a license cooperation agreement signed by the company with ZhenDaiTianqing. As of the six months ending June 30, 2025, the group recognized revenue of 4.7 million yuan for granting license rights to achieve development milestones. Research and development service income is mainly based on a license cooperation agreement signed by the company with ZhenDaiTianqing, where the company provides commissioned research and development services. In the six months ending June 30, 2025, the company recognized 32.5 million yuan of research and development service income based on the relative proportion of efforts or inputs made towards fulfilling obligations compared to the total inputs expected to fulfill those obligations.